<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; AGN</title>
	<atom:link href="http://www.stockbloghub.com/tag/agn/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SLTM) Solta Medical Reports LipoSonix Approval</title>
		<link>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028</link>
		<comments>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:26:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86028</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) reported that Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), has won the U.S. approval for the second-generation LIPOSONIX system for non-invasive waist circumference reduction. Solta announced, in September 2011, the acquisition of Medicis Technologies Corporation in a deal worth $35 million. The acquisition, which is expected to be completed in fourth-quarter 2011, provides Solta with Medicis’ LIPOSONIX system which uses advanced non-invasive ultrasound energy to reduce abdominal fat. Under the agreement, Solta will pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical Buying Medicis Unit</title>
		<link>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359</link>
		<comments>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:05:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83359</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) has agreed to acquire Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), in a deal worth roughly $35 million. Under the agreement, Soltawill pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial milestones. The acquisition, which is subject to customary closing conditions including antitrust clearance, is expected to close in fourth-quarter 2011. Solta plans to finance the transaction through its existing cash and credit facilities. The acquisition provides Solta with Medicis’ LIPOSONIX system, which uses advanced non-invasive ultrasound energy to reduce abdominal fat. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for August 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747</link>
		<comments>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747#comments</comments>
		<pubDate>Fri, 05 Aug 2011 16:18:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[Clorox Corporation]]></category>
		<category><![CDATA[CLX]]></category>
		<category><![CDATA[General Motors]]></category>
		<category><![CDATA[GM]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy Inc.]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[Web.com Group Inc]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WWWW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80747</guid>
		<description><![CDATA[•    NRG Energy (NYSE:NRG) posted Q2 EPS of $2.53, clearly beating the Zacks Consensus Estimate of $0.38 per share. Revenues for the quarter rose 6.8% year-over-year to $2.28 billion, which came in lower than the Zacks Consensus Estimate of $2.7 billion •    Shares of Kraft Foods (NYSE:KFT) opened higher after the company announced plans to split the company into two separate public companies. However, shares of the company lost ground and closed 1.52% lower •    General Motors (NYSE:GM) reported adjusted Q2 EPS of $1.54, beating the Zacks Consensus Estimate of $1.21 per share. Revenues for the quarter rose 18.7% year-over-year to $39.40 billion, exceeding the Zacks Consensus Estimate of $36.61 billion •    Health-care info-tech provider Emdeon Inc (NYSE:EM) is to be acquired by private equity firm Blackstone Group (NYSE:BX). Following ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats &#8211; Revisits Guidance</title>
		<link>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566</link>
		<comments>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566#comments</comments>
		<pubDate>Wed, 03 Aug 2011 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAP Pharmaceuticals Inc]]></category>
		<category><![CDATA[MAPP]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80566</guid>
		<description><![CDATA[Allergan, Inc.’s (AGN) second quarter 2011 earnings of 96 cents per share inched ahead of the Zacks Consensus Estimate by a penny and surpassed the company’s guidance range of 93 – 95 cents. Earnings increased 12.9% from the year-ago quarter. Revenues Revenues increased 13.6% to $1,417.2 million, easily exceeding the Zacks Consensus Estimate of $1,339 million. Specialty pharmaceuticals sales increased 14.0% to $1,155.3 million, with eye care pharmaceutical sales increasing 13.8%. Strong performance of products like Lumigan and Restasis helped drive eye-care sales. Alphagan and Combigan franchise sales went up 4.1% to $108.5 million in the reported quarter. New product Latisse contributed $21.9 million to the second quarter sales. Botox sales increased 16.1% year on year to $418.4 million. Going forward, Allergan is looking to boost Botox sales by gaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for May 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364</link>
		<comments>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364#comments</comments>
		<pubDate>Thu, 05 May 2011 13:56:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMAT]]></category>
		<category><![CDATA[Applied Materials Inc.]]></category>
		<category><![CDATA[CAG]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[ConAgra Foods Inc.]]></category>
		<category><![CDATA[Novellus Systems Inc.]]></category>
		<category><![CDATA[NVLS]]></category>
		<category><![CDATA[PRU]]></category>
		<category><![CDATA[Prudential Financial Inc.]]></category>
		<category><![CDATA[R.R. Donnelley & Sons Company]]></category>
		<category><![CDATA[RAH]]></category>
		<category><![CDATA[Ralcorp Holdings Inc.]]></category>
		<category><![CDATA[RRD]]></category>
		<category><![CDATA[Varian Semiconductor Equipment Associates Inc]]></category>
		<category><![CDATA[VSEA]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73364</guid>
		<description><![CDATA[•    R.R. Donnelley &#38; Sons (NYSE:RRD) reported Q1 EPS of $0.33, missing the Zacks Consensus Estimate of $0.36 per share. Revenues for the quarter rose 7% year-over-year to $2.58 billion, lower than the Zacks Consensus Estimate of $2.634 billion •    The Williams Companies (NYSE:WMB) reported Q1 EPS of $0.36 ex-items today, slightly higher than the Zacks Consensus estimate of $0.35 per share •    Prudential Financial (NYSE:PRU) reported Q1 earnings per common share of $1.69 ex-items, beating the Zacks Consensus Estimate for $1.48 per share. Revenues for the quarter grew 28% year-over-year to $9.20 billion, above the Zacks Consensus Estimate of $8.196 billion •    CBS Corporation (NYSE:CBS) increased 7.19% to close the day at $27.21 after the company doubled its dividend and reported first- quarter profits that beat analysts’ estimates •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for April 04, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/04/agn-company-news-for-april-04-2011-corporate-summary/70605</link>
		<comments>http://www.stockbloghub.com/2011/04/04/agn-company-news-for-april-04-2011-corporate-summary/70605#comments</comments>
		<pubDate>Mon, 04 Apr 2011 17:56:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[ALEX]]></category>
		<category><![CDATA[Alexander & Baldwin Inc.]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[ICE]]></category>
		<category><![CDATA[Intercontinental Exchange]]></category>
		<category><![CDATA[Interpublic Group of Companies Inc]]></category>
		<category><![CDATA[IPG]]></category>
		<category><![CDATA[MAIN]]></category>
		<category><![CDATA[Main Street Capital Corporation]]></category>
		<category><![CDATA[MBRG]]></category>
		<category><![CDATA[Middleburg Financial Corporation]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[Nyse Euronext Inc]]></category>
		<category><![CDATA[NYX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70605</guid>
		<description><![CDATA[• The Nasdaq OMX Group (NASDAQ:NDAQ) and the IntercontinentalExchange (NYSE:ICE) announced a joint proposal to acquire NYSE Euronext (NYSE:NYX) for $42.50 per share in cash and stock, or approximately $11.3 billion, based on the closing prices of the respective stocks as of March 31, 2011 • RW Baird initiated coverage on Main Street (NASDAQ:MAIN) with an Outperform rating • JMP Securities upgraded Sabra Healthcare (NASDAQ:SBRA) to Outperform from Market Perform • Roth Capital initiated coverage on Yuhe International (NASDAQ:YUII) with a Buy rating • Wells Fargo upgraded Alexander &#38; Baldwin (NASDAQ:ALEX) to Market Perform from Underperform • Leerink upgraded Allergan (NYSE:AGN) to Outperform from Market Perform • Deutsche Bank initiated coverage on Huntington Ingalls (NYSE:HII) with a Hold rating • BB&#38;T Capital downgraded Middleburg Financial (NASDAQ:MBRG) to Hold from Buy • Deutsche Bank downgraded Omeros (NASDAQ:OMER) to Hold from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/agn-company-news-for-april-04-2011-corporate-summary/70605/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for October 18, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/10/18/agn-company-news-for-october-18-2010-corporate-summary/55548</link>
		<comments>http://www.stockbloghub.com/2010/10/18/agn-company-news-for-october-18-2010-corporate-summary/55548#comments</comments>
		<pubDate>Tue, 19 Oct 2010 05:09:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Northeast Utilities]]></category>
		<category><![CDATA[NST]]></category>
		<category><![CDATA[NSTAR]]></category>
		<category><![CDATA[NU]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55548</guid>
		<description><![CDATA[• Halliburton (NYSE:HAL) reported third quarter earnings of $0.58 a share, $0.02 higher than expected on a 30% revenue climb to $4.66 billion, above projections of $4.63 billion • Hasbro (NYSE:HAS) posted third quarter interims 5 cents above estimates at $1.09 on a 2.7% revenue increase to $1.31 billion, ahead of estimates of $1.29 billion • Northeast Utilities (NYSE:NU) announced plans to acquire NSTAR (NYSE:NST) for $4.17 billion • Allergan (NYSE:AGN) received FDA approval for use of its Botox treatment for chronic migraine headaches • Citigroup (NYSE:C) posted third quarter profits of $0.08, up from estimates of $0.06 on revenues of $20.74 billion, below expectations of $21.15 billion • St. Jude Medical (NYSE:STJ) announced intentions to buy AGA Medical Holdings (NASDAQ:AGAM) for $20.80 per share in a cash and share deal valued at $1.3 billion • Rio ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/18/agn-company-news-for-october-18-2010-corporate-summary/55548/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals Earnings Beat Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041</link>
		<comments>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041#comments</comments>
		<pubDate>Wed, 07 Apr 2010 23:00:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33041</guid>
		<description><![CDATA[Spectrum Pharmaceuticals (SPPI) reported fourth quarter earnings per share of 20 cents. The company posted a loss of 28 cents in the prior-year quarter. The swing from loss to profit was possible due to an accounting restatement made by the company to reclassify common stock warrants from equity to liability, resulting in an income of $19.8 million. Excluding the impact of the account restatement, Spectrum reported a loss of 19 cents compared to the Zacks Consensus Estimate of a loss of 20 cents. For 2009, the company reported a loss per share of 48 cents compared to a loss of 45 cents in 2008. During the fourth quarter and full year, Spectrum reported revenues of $8.6 million (year-over-year growth of 7.1%) and $38.02 million (a 32.5% growth), respectively. Spectrum has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Enters Agreement With Serenity Pharmaceuticals &#8211; Expands Urologics Portfolio</title>
		<link>http://www.stockbloghub.com/2010/04/06/agn-allergan-enters-agreement-with-serenity-pharmaceuticals-expands-urologics-portfolio/32911</link>
		<comments>http://www.stockbloghub.com/2010/04/06/agn-allergan-enters-agreement-with-serenity-pharmaceuticals-expands-urologics-portfolio/32911#comments</comments>
		<pubDate>Tue, 06 Apr 2010 21:14:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32911</guid>
		<description><![CDATA[Allergan, Inc. (AGN) recently entered into an agreement with Serenity Pharmaceuticals, for the development and commercialization of Ser-120, which is being studied for the treatment of nocturia. Nocturia, which is characterized by frequent urination during the night, is a common urological disorder observed in adults. Allergan will make an upfront payment of $43 million to Serenity for exclusive worldwide rights for the development, manufacture and commercialization of Ser-120. The deal covers all potential indications excluding pediatric bedwetting. In addition to the upfront payment, Serenity is eligible to receive up to $122 million in development and regulatory milestone payments, sales milestones and royalty payments on worldwide sales. The deal is in-line with Allergan’s aim to establish itself in the genitourinary (GU) market ahead of the potential launch of Botox for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/agn-allergan-enters-agreement-with-serenity-pharmaceuticals-expands-urologics-portfolio/32911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Completes Product Deals</title>
		<link>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393</link>
		<comments>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:14:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32393</guid>
		<description><![CDATA[Alcon, Inc. (ACL) recently announced that it has acquired rights to two topical eye care products, Durezol and Zyclorin, from Sirion Therapeutics, Inc. Alcon also said that it is evaluating options to acquire another product, Zirgan, which is approved for the treatment of acute herpetic keratitis or corneal ulcers. While Durezol is approved by the US Food and Drug Administration (FDA), Zyclorin is being developed for the treatment of dry eye and other ocular surface diseases. Alcon has rights for Zyclorin in all territories excluding Latin America. Alcon said that it will take charge of all marketing, promotion and sales of Durezol in the United States immediately. Durezol is approved for the treatment of inflammation and pain associated with eye surgery. This agreement is in-line with the company&#8217;s goal to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Wins FDA Approval For Label Expansion on Botox</title>
		<link>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504</link>
		<comments>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:51:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30504</guid>
		<description><![CDATA[Allergan, Inc. (AGN) recently received good news with the US Food and Drug Administration (FDA) granting approval to Botox for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. The FDA approval comes after the company submitted additional data following the receipt of a complete response letter from the agency in May 2009. Botox was originally developed for the treatment of certain ophthalmic movement disorders, but has since seen strong growth thanks to approval for additional indications. Although Botox is known more for its cosmetic uses, therapeutic indications accounted for 52% of total Botox sales in 2009. Allergan has been working on gaining approval for additional indications for Botox. Botox sales declined marginally in 2009 mainly due to weak consumer spending, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Signs Deal With Allergan</title>
		<link>http://www.stockbloghub.com/2010/03/04/bmy-bristol-myers-squibb-signs-deal-with-allergan/29800</link>
		<comments>http://www.stockbloghub.com/2010/03/04/bmy-bristol-myers-squibb-signs-deal-with-allergan/29800#comments</comments>
		<pubDate>Fri, 05 Mar 2010 00:13:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29800</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) and Allergan, Inc. (AGN) entered into an agreement to develop and commercialize AGN-209323, Allergan&#8217;s mid-stage pipeline candidate. AGN-209323 is being developed to treat neuropathic pain, or chronic pain usually accompanied by tissue injury. AGN-209323 was discovered as part of collaboration between Allergan and ExonHit Therapeutics SA. The pain is common in people suffering from arthritis, cancer and nerve damage. The drug can be administered orally. The deal would see Allergan granting Bristol-Myers exclusive global rights to develop, manufacture and commercialize AGN-209323 as well as backup compounds. Under the terms of the deal, Bristol-Myers would make an upfront payment of $40 million for the rights to the candidate. Furthermore, Allergan stands to get another $373 million from Bristol-Myers in the event of AGN-209323 advancing through clinical development ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/bmy-bristol-myers-squibb-signs-deal-with-allergan/29800/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats The Street &#8211; Outlook Disappoints</title>
		<link>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999</link>
		<comments>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999#comments</comments>
		<pubDate>Thu, 04 Feb 2010 21:31:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26999</guid>
		<description><![CDATA[Allergan, Inc. (AGN) reported fourth quarter earnings of 78 cents per share, a cent above the Zacks Consensus Estimate. While earnings increased 2.6% from the year-ago quarter, revenues increased 15.9% to $1,224.3 million. Allergan also declared a fourth quarter dividend of 5 cents per share. Earnings for the full year came in at $2.78 per share, a cent above the Zacks Consensus Estimate and 8.2% above the year-ago period. Full year revenues increased 2.3% to $4,503.6 million. Segment Performance Specialty pharmaceuticals sales increased 17.7% to $995 million in the fourth quarter with full year sales increasing 5.2% to $3,683.8 million. Eye care pharmaceutical sales increased 21.2% during the fourth quarter. Strong performance of the Alphagan and Combigan franchise and products like Lumigan and Restasis helped drive eye care sales. New ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Strengthens Product Pipeline</title>
		<link>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460</link>
		<comments>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460#comments</comments>
		<pubDate>Wed, 20 Jan 2010 22:46:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25460</guid>
		<description><![CDATA[Alcon, Inc. (ACL) continues to work on expanding its product portfolio. The company recently entered into an agreement with Sirion Therapeutics, Inc. for the purchase of rights to two topical eye care products, Durezol and Zirgan. Both products have been approved by the US Food and Drug Administration (FDA). The deal is scheduled to close in the first quarter of 2010. While Durezol is approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is approved for the treatment of acute herpetic keratitis or corneal ulcers. Alcon also gained global rights, excluding Latin America, to pipeline candidate Zyclorin, which is being developed for the treatment of dry eye and other ocular surface diseases. This agreement is in-line with the company&#8217;s goal to expand its product portfolio and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats Estimates &#8211; Raises Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274</link>
		<comments>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274#comments</comments>
		<pubDate>Sun, 01 Nov 2009 21:28:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19274</guid>
		<description><![CDATA[Allergan, Inc. (AGN) reported third quarter earnings of 70 cents per share, a cent above the Zacks Consensus Estimate and 7.7% above the year-ago earnings of 65 cents. We were pleased to see total revenues increase 3.9% to $1,141.3 million in the reported quarter. Specialty pharmaceuticals sales increased 7.8% to $940.6 million. Eye care pharmaceutical sales increased 4.8%. The strong performance of products like Lumigan and Restasis was offset by weakness in the Alphagan and Combigan franchise. Importantly, we were encouraged to see a recovery in Botox sales, which increased 3% from the year-ago period to $327.8 million. Botox sales had been declining during the past few quarters mainly due to weak consumer spending and concerns regarding its safety record. The recovery in Botox sales resulted in Allergan raising its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Continues to Grow Pipeline</title>
		<link>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787</link>
		<comments>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:34:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18787</guid>
		<description><![CDATA[Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop Potentia&#8217;s leading drug candidate, POT-4, for the treatment of AMD. Alcon also gained the right to acquire Potentia’s shares on the achievement of certain development milestones and if Alcon opts to continue with the development of POT-4. Alcon will make upfront payments to Potentia for the initial license and option rights. Potentia is also entitled to receive future payments based on the achievement of several clinical and global regulatory approval milestones for different therapeutic indications and on Alcon&#8217;s decision to proceed with development. Potentia will also receive royalties based on sales of any ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical&#8217;s Laser Device Approved by The FDA</title>
		<link>http://www.stockbloghub.com/2009/10/15/sltm-solta-medicals-laser-device-approved-by-the-fda/17788</link>
		<comments>http://www.stockbloghub.com/2009/10/15/sltm-solta-medicals-laser-device-approved-by-the-fda/17788#comments</comments>
		<pubDate>Thu, 15 Oct 2009 21:48:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Candela Corporation]]></category>
		<category><![CDATA[CLZR]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17788</guid>
		<description><![CDATA[After the closing bell on Wednesday, Solta Medical Inc. (SLTM) announced that the U.S. Food and Drug Administration (FDA) approved its device to clear pigmentation and other superficial skin conditions. The device, called the Fraxel re:store Dual Laser System, can be used both on the face and large body areas to clear pigmentation through a single treatment. Solta has already received approval for the device with 1550 nanometer (nm) wavelength for skin resurfacing and treatment of pigmented lesions and certain other dermatological conditions. The present FDA 510(k) clearance is for the Fraxel 1927 nm laser for dermatological procedures requiring the coagulation of soft tissue. Prior to its approval, laser skin resurfacing procedures were largely limited to the face. The approval of the new 1927 nm wavelength increases the areas of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/sltm-solta-medicals-laser-device-approved-by-the-fda/17788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Files Federal Lawsuit</title>
		<link>http://www.stockbloghub.com/2009/10/06/agn-allergan-files-federal-lawsuit/16665</link>
		<comments>http://www.stockbloghub.com/2009/10/06/agn-allergan-files-federal-lawsuit/16665#comments</comments>
		<pubDate>Tue, 06 Oct 2009 19:17:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16665</guid>
		<description><![CDATA[Allergan Inc. (AGN) recently filed a lawsuit seeking a ruling that the company should be allowed to share truthful and relevant information on Botox with physicians so as to help them evaluate the risks and benefits associated with certain off-label therapeutic uses of the treatment. The lawsuit does not relate to the cosmetic use of Botox. The declaratory relief action has been filed by the company in the United States District Court for the District of Columbia . The company is contending that the government&#8217;s ban on off-label drug marketing to doctors violates the First Amendment and is inconsistent with the Federal Food, Drug &#38; Cosmetic Act. Botox is approved for several uses by the FDA. In addition to its use as a wrinkle treatment, it is approved for ophthalmic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/06/agn-allergan-files-federal-lawsuit/16665/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Aquires Swiss Company and Expands Pipeline</title>
		<link>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568</link>
		<comments>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:17:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15568</guid>
		<description><![CDATA[Earlier this week, Alcon Inc. (ACL) signed a definitive agreement for the acquisition of Swiss biotech company ESBATech AG. Alcon will pay $150 million in cash at closing. Besides this, Alcon may pay up to $439 million on the achievement of future research and development milestones. With this acquisition, Alcon will gain access to ESBATech’s proprietary antibody fragment technology, which is used for the development of compounds for the treatment of eye diseases like age-related macular degeneration, diabetic macular edema, glaucoma, dry eye and uveitis. ESBATech has several stable and soluble single-chain antibody fragments in development. ESBATech’s lead antibody fragment, ESBA105, is a recombinant humanized scFv antibody fragment directed against human tumor necrosis factor-alpha (TNF?). ESBA105 is being developed for a number of therapeutic indications and is currently in a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Expands Ophthalmic Portfolio</title>
		<link>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341</link>
		<comments>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:59:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14341</guid>
		<description><![CDATA[Abbott (ABT) yesterday entered into a definitive agreement whereby it will acquire Visiogen, Inc., a privately-held company, for $400 million in cash. Visiogen is focused on the development of innovative products for cataract and refractive patients. The deal will provide Abbott with access to Visiogen’s next-generation accommodating intraocular lens (IOL) technology, which helps address presbyopia in cataract patients. Visiogen’s first commercial application, Synchrony, is currently available in Europe and under Food and Drug Administration (FDA) review in the U.S. Synchrony is designed to deliver improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity. This deal is in-line with Abbott’s goal of strengthening its ophthalmic portfolio. As a reminder, Abbott entered the ophthalmology market earlier this year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals&#8217;s Eye Drug Shows Success</title>
		<link>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559</link>
		<comments>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559#comments</comments>
		<pubDate>Thu, 27 Aug 2009 19:51:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13559</guid>
		<description><![CDATA[ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market. The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Receives FDA Warning</title>
		<link>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287</link>
		<comments>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:23:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13287</guid>
		<description><![CDATA[On Aug. 21, Allergan, Inc. (AGN) received a warning letter from the U.S. Food and Drug Administration’s (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) regarding a misleading advertisement used by the company for its acne treatment Aczone Gel, 5%. Aczone is a topical gel formulation, which is approved in the U.S. and Canada for the treatment of acne vulgaris in patients 12 years and older. Allergan acquired the product in July 2008 from QLT Inc. for $150 million in order to bolster its skin care franchise. In the warning letter, the FDA stated that the claims made by the company in the advertisement are a misrepresentation of the clinical results. According to the agency, the benefits of Aczone have been overstated. In the advertisement, Allergan claims that Aczone ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

